The RNA interference (RNAi)
INTRODUCTION
RNA interference (RNAi) occurs in a variety of organisms, including Caenorhabditis elegans, Trypanosoma brucei, plants, Drosophila, planaria, zebra®sh and mouse embryos. In most of these organisms, the injection of a doublestranded RNA (dsRNA) longer than 500 bp speci®cally suppresses the expression of the gene with the corresponding DNA sequence, but has no effect on genes with unrelated sequences (1±10).
RNAi is initiated by the RNase III-like nuclease Dicer, which promotes processive cleavage of long dsRNAs into 21±23-nt short interfering RNAs (siRNAs) with 2-nt 3¢ overhangs (11±15). Subsequently, the siRNAs are incorporated into an RNA-induced silencing complex (RISC), identi®ed in Drosophila, and the protein±RNA effector nuclease complex recognizes and destroys the target mRNAs (16±18).
The use of this RNAi in mammalian cells appeared to be of limited utility, because dsRNAs longer than 30 bp trigger interferon responses through the activation of dsRNAdependent protein kinase (PKR) and 2¢,5¢-oligoadenylate (2-5A) synthetase (19±21). To overcome this non-speci®c effect in mammalian cells, it has recently been found that 21±23-nt siRNAs with 2-nt 3¢ overhangs exhibit an RNAi effect (22) . Transfection of synthetic siRNAs into mammalian cells effectively inhibits the endogenous genes in a sequencespeci®c manner (22±24). Lee et al. have reported the inhibition of HIV-1 replication by the expression of small interfering RNAs targeted against HIV-1 rev in human cells (25) .
Several RNA-based antiviral therapies are being studied for HIV treatments, using ribozyme and antisense approaches (26±28). However, dsRNA provides a more reliable method of viral and reporter gene inactivation than antisense RNA (29) . Furthermore, the longer dsRNA-mediated inhibition of gene expression is still being studied in mammalian systems. Microinjection of dsRNA into mouse oocytes or early embryos results in the speci®c inhibition of the activities of both maternally and zygotically expressed proteins (9, 10) . Recently, Billy et al. reported that the RNAi response could be induced effectively by long dsRNA in non-differentiated mouse cells grown in culture (30) . In addition, Billy et al. demonstrated that extracts prepared from mouse embryonal carcinoma (EC) cells catalyzed the processing of dsRNA intõ 23-nt RNAs and that the processing enzyme, Dicer, is localized in the cytoplasm of EC and HeLa cells.
In this study, we used a long dsRNA, in place of antisense DNA (31, 32) , to interfere with the expression of HIV-1 genes. We found that the greatest inhibitory effects were detected with 531 bp E2-dsRNA containing the major CD4-binding domain sequence of gp120, as the target of the HIV-1 env gene. We also found that the long dsRNA caused the sequencespeci®c inhibition of HIV-1 replication. Especially, the E2-dsRNA dramatically inhibited the expression of the HIV-1 p24 antigen in PBMCs for a relatively long time.
MATERIALS AND METHODS
Plasmid and PCR template used for RNA synthesis Plasmid pNL4-3 was used as the PCR template for the synthesis of dsRNAs corresponding to the gag and env genes. PCR templates for dsRNA synthesis targeting the ®re¯y luciferase (luc) reporter gene (Photinus pyralis, Luc, 1032±1562, 531 bp) were ampli®ed from pEGFPLuc (Clontech). The transcription templates were linear doublestranded DNA (dsDNA) with blunt or 5¢-protruding ends. The templates used for dsRNA synthesis were the products of PCRs with primers designed to amplify limited regions of the cDNA sequence for each gene. Each primer contained an SP6 promoter sequence (CATACGATTTAGGTGACACTATAG) and a T7 promoter sequence (TAATACGACTCACTATAG) on its 5¢ end. Sense and antisense RNAs were synthesized in vitro with the SP6 and T7 polymerases, using the AmpliScribe Transcription Kit (Epicentre Technologies). DNA templates were then removed by DNase I treatment. The RNA products were extracted with phenol/chloroform and then precipitated in ethanol. The in vitro transcription products were resolved by electrophoresis in a 1% agarose gel prepared with denaturing buffer. For annealing, equimolar quantities of sense and antisense RNAs were mixed in annealing buffer (10 mM Tris pH 7.4, 0.1 mM EDTA), heated to 90°C for 1 min and incubated at 37°C for 12±16 h. The formation of dsRNA was con®rmed by its migration on a 1% agarose gel in TBE.
Cell culture and RNA interference assays COS, HeLa-CD4 + and ACH2 cells were grown in RPMI 1640 medium (Sigma) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine at 37°C under a 5% CO 2 atmosphere. Human peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation, grown in RPMI 1640 medium supplemented with 10% FBS, and activated with 1 mg/ml phytohemaggulutinin (PHA) (Seikagaku Corp.) for 3 days in the presence of IL-2 (100 U/ml; Shionogi) at 37°C. For the p24 accumulation assays, PHA-stimulated PBMCs were infected with the HIV-1 NL4-3 virus at a multiplicity of infection (MOI) of 0.001 in the presence of various concentrations of the dsRNAs. At 4, 7, 10 or 14 days after infection, culture supernatants containing the viruses were removed and the amount of p24 was measured by an HIV-1 p24 CLEIA assay (Lumipulse; Fujirebio Inc.) (33) . Fresh medium was then added with one-half volume of culture medium and the cells were transfected with the indicated amounts of dsRNA by using the TransMessenger Transfection Reagent (Qiagen), as described by the manufacturer. The plasmid pNL4-3 is an HIV-based infectious vector, which was puri®ed with the plasmid Maxi-Prep Kit (Sigma), followed by phenol extraction and ethanol precipitation. Twenty-four hours before transfection, adherent cells were seeded in 6-well multiwell plates at a density of 2 Q 10 5 cells/well. COS cells were transfected with 2 mg dsRNA and 2 mg pNL4-3, using 2 ml of Lipofectin (Gibco BRL) and 3 ml of FuGENE 6 (Roche), according to the manufacturers' optimized protocols. After a 72 h incubation, the virus replication was monitored in the culture supernatants with the HIV-1 p24 CLEIA assay. For the infection of HeLa-CD4 + cells, 2 Q 10 5 cells were seeded into 6-well multiwell plates 24 h before infection and then were infected with the HIV-1 NL4-3 virus at a MOI of 0.5. After a 16 h infection, the cells were washed and treated with dsRNA at a 2 mg concentration in the culture medium. HeLa-CD4 + cells were transfected at~24 h intervals and were asssayed 7 days after infection.
RNA isolation and RT±PCR assay
The reverse transcription and the PCR analysis were performed with total RNA from COS cells (prepared with the GenElute Mammalian Total RNA kit; Sigma) as the template (1 mg/reaction). These templates were ampli®ed for one cycle of 60°C for 30 min and 94°C for 2 min, 40 cycles of 94°C for 1 min and 50°C for 1.5 min and one cycle of 50°C for 1 min with env gene-speci®c primers. The primers were 5¢-ACA-GCTGAACACATCTGTAGAAATTAATTG-3¢ and 5¢-GTT-GTTATTACCACCATCTCTTGTTAATAG-3¢. The ampli®ed DNA was subjected to electrophoresis in a 1% agarose gel and was visualized by ethidium bromide staining.
RESULTS AND DISCUSSION
The ef®cient cellular uptake of the dsRNAs is a critical step to enable targeting to the mRNA. Using COS cells, we examined the cellular uptake of¯uorescently labeled E2-dsRNA with several kinds of transfection reagents (FuGENE 6, Lipofectin and Gene PORTER 2) at 37°C for 24 and 72 h. The cells were washed twice with PBS, resuspended in PBS containing 1% paraformaldehyde and analyzed by the FACS Calibur and CellQuest software. When we used Lipofectin as the transfection reagent, after 24 h, 94% of the COS cellassociated¯uorescence signal was found, while after 72 h it had only decreased to 84%, which might explain the enhanced RNAi effect (data not shown). To test for silencing of the HIV-1 gene, we chose Lipofectin as the transfection reagent.
To test for silencing, we designed six longer dsRNAs containing the HIV-1 gag (G1±G3) and env genes (E1±E3) (Fig. 1A) . We also designed a control long dsRNA, which included the ®re¯y luciferase gene (Photinus pyralis, Luc dsRNA, 1032±1562, 531 bp). Sense (ss) and antisense (as) RNAs were transcribed in vitro from PCR products and annealed to each other to produce the dsRNA. The ssRNAs, asRNAs and dsRNAs were each tested for their ability to suppress HIV-1 expression speci®cally. Using Lipofectin (Gibco), dsRNA duplexes were co-transfected into COS cells with the HIV-1 expression vector pNL4-3. The virus production in the culture supernatant was assessed by the HIV-1 p24 antigen assay at 3 days, and was related to the amount produced in the absence of dsRNA. The six longer dsRNAs containing the HIV-1 gag (G1±G3) and env sequences (E1±E3) speci®cally reduced the p24 expression by~10-to 23-fold as compared to the untreated control cells. Notably, the three dsRNAs targeted to the HIV-1 env gene (E1±E3) inhibited p24 expression more effectively than those targeted to the HIV-1 gag gene (G1±G3) (Fig. 1B) . We also investigated the sequence-speci®c inhibition of HIV-1 gene expression, using the Luc-dsRNA as the control dsRNA. The Luc-dsRNA showed higher expression of the p24 antigen than the six dsRNAs targeted to the HIV-1 gag (G1±G3) and env genes (E1±E3) (Fig. 1B) . However, the Luc-dsRNA exhibited very low inhibition of HIV-1 replication. Some inhibition by the control Luc-dsRNA might have occurred if it caused the activation of a dsRNA-dependent enzyme, such as PKR or 2-5A synthetase. The greatest inhibitory effects were detected with the 531 bp E2-dsRNA containing the major CD4-binding domain sequence of gp120, as the target of the HIV-1 env gene.
We also assessed whether the RNAi was dose dependent. COS cells were transduced with 0.5±4 mg of the E2-ssRNA, asRNA or dsRNA and the HIV-1 expression vector pNL4-3, using Lipofectin. As expected, the E2-dsRNA exhibited the HIV-1-dependent dsRNA-mediated inhibition in a dosedependent manner (Fig. 2) . With this result, we con®rmed the effectiveness of the dsRNAs by their dose dependence, with the best response at 2 mg. Interestingly, the E2-asRNA also reduced the p24 expression, with a similar dosedependent ef®ciency. The E2-ssRNA was incapable of inhibiting HIV-1 gene expression, even when transfected with an excess of the minimum saturating dsRNA concentration.
To characterize the relationship between RNAi and asRNAs further, we compared the inhibitory effects of six longer dsRNAs targeted to the HIV-1 gag and env genes with those of the corresponding ssRNAs and asRNAs. A comparison of the effects of the ss-, as-and dsRNAs containing the HIV-1 gag sequences (G1±G3) is shown in Figure 3A . In comparison, there was no dramatic difference in the p24 antigen suppression levels between the dsRNAs and asRNAs (G1±G3), as shown in Figure 3A . The G1-ssRNA was ineffective in reducing the amount of p24 antigen. In addition, the G2-and G3-ssRNAs reduced the amount of p24 antigen by only 2-to 3-fold. Figure 3B shows a comparison of the effects of ss-, as-and dsRNAs containing the HIV-1 env sequences (E1±E3). The three dsRNAs targeted to the HIV-1 env genes (E1±E3) effectively inhibited HIV-1 gene expression more than 2-to 3-fold relative to the asRNAs. In contrast, the three control ssRNAs suppressed the p24 expression by onlỹ 2-fold. Although the asRNA was able to inhibit HIV-1 gene expression, the results presented in Figure 3 indicate that the dsRNA is a more potent inhibitor than the asRNA. These results strengthen the conclusion that the dsRNA is more effective in targeting HIV-1 genes than the asRNA. The dsRNA acted in a sequence-speci®c manner and did not affect the expression from the non-complementary control templates.
Moreover, we examined the HIV-1 mRNA levels to identify the contribution of the dsRNA-mediated speci®c RNAi. RT±PCRs were used to establish the level of uncleaved HIV-1 mRNA. Equal amounts of total RNA from COS cells, transfected with E2-dsRNA or ssRNA and pNL4-3 at a weight (mg) ratio of 1:1, were subjected to RT±PCR analysis. HIV-1 env-speci®c DNA primers (sense, 7072±7101; antisense, 7571±7600) were used to amplify a 529 bp (7072±7600) fragment in the transcripts. The COS cells transfected with the E2-dsRNA showed an 85% reduction in HIV-1 transcripts. However, the E2-ssRNA did not reduce the abundance of HIV-1 mRNA (Fig. 4) . The reduction in the functional fulllength HIV-1 mRNA is consistent with a dsRNA-mediated interference effect at the post-transcriptional level. The results of these experiments indicate that dsRNA causes a speci®c reduction in the target mRNA levels.
In addition, to clarify the ability of dsRNA to inhibit viral replication in HIV-1-infected cells, we used the HeLa-CD4 + cell line and the E2-dsRNA. HeLa-CD4 + cells were infected with the HIV-1 NL4-3 virus at a MOI of 0.5. After a 16 h infection, the cells were washed and co-transfected with E2-ss-, as-or dsRNA at a 2 mg concentration, using Lipofectin. In the cells treated with the E2-dsRNA, the virus replication was inhibited by~70-fold, as compared to the untreated control cells (Fig. 5) . The long single-stranded asRNA also had highly inhibitory effects, but the ssRNA had virtually no effect. In this infection experiment, we also observed sequence-speci®c, dsRNA-mediated silencing.
Next, the inhibitory activity of the E2-dsRNA against HIV-1 NL4-3 replication in PBMCs was also demonstrated by a p24 accumulation assay of culture supernatants from virusinfected cells. The dose dependence of the dsRNA effect was investigated in PBMCs, using E2-dsRNA. PHA-stimulated PBMCs were infected with the HIV-1 NL4-3 virus at a MOI of 0.001, in the presence of various concentrations of the dsRNAs. At 10 days post-infection, the amount of p24 antigen was measured by an HIV-1 p24 CLEIA assay. As expected, the E2-dsRNA (0.1±10 mg) reduced the p24 antigen levels in a dose-dependent manner (Fig. 6A) . We next measured the persistence of the dsRNA silencing effect in PBMCs over a 14 day period. PHA-stimulated PBMCs were infected with the HIV-1 NL4-3 virus at a MOI of 0.001 in the presence of the E2-dsRNA (10 mg). At 4, 7, 10 and 14 days after infection, culture supernatants containing the viruses were removed and the amount of p24 was measured by an HIV-1 p24 CLEIA assay. As shown in Figure 6B , the E2-dsRNA (10 mg) was also effective against HIV-1 NL4-3 replication for a relatively long time (14 days). These ®ndings highlight the general utility of RNAi technology in suppressing HIV-1 expression.
To investigate the inhibitory mechanism of dsRNA on the replication cycle of HIV-1, we examined the anti-retroviral effect of a longer E2-dsRNA on ACH2 cells. The ACH2 cell line, a model for chronic HIV-1 infection, possesses a single integrated copy of the HIV-1 strain LAI and can be induced to produce virus by a variety of stimuli (34) . ACH2 cells were transfected with E2-ss-, as-or dsRNAs and were stimulated with 10 nM (®nal concentration in the cell culture medium) tetradecanoyl phorbol acetate (TPA). In this induction system, the E2-dsRNA was less effective in inhibiting virus replication than in the transient system described above (data not shown). These observations suggest that dsRNA may effectively prevent early steps prior to integration, rather than later post-integration steps, in the HIV-1 infection cycle. RNAi is likely to re¯ect natural defenses against viruses, as a self-regulating mechanism of gene expression (15, 35, 36) . However, the mechanisms of the RNAi process in mammalian cells remain unresolved.
In this report, we have shown that dsRNA can be successfully used as a new anti-HIV-1 agent in HIV-1-infected cells. In the case of COS cells co-transfected with both the HIV-1 pNL4-3 proviral DNA and dsRNA, the dsRNA was a more potent inhibitor than the single-stranded asRNA in promoting the inhibition of HIV-1 replication. We also demonstrated that dsRNA signi®cantly suppressed HIV-1 infection in HeLa-CD4 + cells and PBMCs for a relatively long period of time. Thus, we suggest that this longer dsRNAmediated speci®c interference in HIV-1-infected cells may provide a new strategy for anti-HIV-1 gene therapy.
